<DOC>
	<DOC>NCT00688896</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of two dose levels of JTT-705 when co-administered with pravastatin 40 mg on HDL-C and LDL-C and the inhibition rate of CETP activity and to document short term safety.</brief_summary>
	<brief_title>Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Dalcetrapib</mesh_term>
	<criteria>Patients having lipid values as indicated below: HDLC less than 1.6 mmol/L (60 mg/dL) TG less than 4.5 mmol/L (400 mg/dL) LDL more than 4.0 mmol/L (160 mg/dL) Patients with CHD or CHD risk equivalent Male and females between 18 and 65 years of age (female patients must be postmenopausal, surgically sterile or using an acceptable form of contraception) Body Mass Index of â‰¥ 35 kg/m2 Females that are pregnant or breastfeeding, and females of child bearing potential who are not using an effective method of contraception Concomitant use of medications identified in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>